BACTI-B Bactiguard Holding AB (publ)
Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas. The company also has a portfolio of wound management products, such as Hydrocyn Aqua, an antimicrobial solution and gel for acute, chronic, and infected wounds; and surgical sutures comprising non-absorbable, natural absorbable, synthetic absorable, and specialty sutures. It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded. The company has licensed partnership with Becton, Dickinson & Company for urinary catheter bardex IC and lubrisil IC; Well Lead Medical for catheters and tubes; and Zimmer Biomet for orthopedic trauma implants. It operates in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally. The company was founded in 2005 and is headquartered in Stockholm, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About Bactiguard Holding (STO: BACTI-B)
›
Bactiguard Holding (STO: BACTI-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 166 employees.
The shares were at 15.10 SEK on 19 November 2026, down 10.9% over 52 weeks. Its 52-week range is 14.00 SEK to 21.60 SEK: the price is 30.1% below the high and 7.9% above the low.
At a market capitalisation of 539.96M SEK, it trades at 68.6 times trailing earnings and 167.8 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a premium of 168% for BACTI-B.
Bactiguard Holding reports return on equity of -2.5%, an operating margin of 3.2% and revenue up 21.2% year over year.
Its debt exceeds its cash by 98.70M SEK, a debt-to-equity ratio of 0.52. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. One analyst covers the stock; their mean price target of 23.00 SEK is 52.3% above the current price. The next earnings report is expected on 4 February 2027.